On some new or rare spider species from Lesbos, Greece (Araneae: Agelenidae, Amaurobiidae, Corinnidae, Gnaphosidae, Liocranidae)

In this paper, three new spider species are described from the Greek Aegean island Lesbos: Tegenaria maelfaiti sp. nov. (Agelenidae), Amaurobius lesbius sp. nov. (Amaurobiidae) and Agroeca parva sp. nov. (Liocranidae), as well as the unknown male of Arabelia pheidoleicomes Bosselaers, 2009 (Corinnidae). Diagnostic features and notes on ecology and distribution of these species are given. Two new records for the island are provided, such that currently 300 spider species are known from Lesbos

Description of Cithaeron dippenaarae sp. n. from Morocco (Araneae: Cithaeronidae)

Cithaeron dippenaarae sp. n. is described from both sexes. The species occurs in stony regions in the south of Morocco

On the spider species described by L. Koch in 1882 from the Balearic Islands (Araneae)

Examination of the L. Koch collection of the Zoological Museum in Berlin allows us to propose the following new synonyms and combinations: Erigone marina L. Koch, 1882 = Oedothorax fuscus (Blackwall, 1834) n. syn.; Theridion elimatum L. Koch, 1882 = Enoplognatha diversa (Blackwall, 1859) n. syn.; Liocranum variabilis Wunderlich, 2008 = Zora inornata L. Koch, 1882 n. syn. = Liocranum inornatum n. comb.; Lycosa perspicax L. Koch, 1882 = Arctosa fulvolineata (Lucas,1846) n. syn.; Alopecosella Roewer, 1960 = Arctosa C. L. Koch, 1847 n. syn.; Lycosa subhirsuta L. Koch, 1882 = Arctosa lacustris (Simon, 1876) n. syn.; Philodromus vegetus L. Koch, 1882 = Thanatus vulgaris Simon, 1870 n. syn.; Ozyptila bicuspis Simon, 1932 = Ozyptila furcula L. Koch, 1882 n. syn.; Haplodrassus maroccanus Denis, 1956 = Drassus parvulus L. Koch, 1882 n. syn. = Haplodrassus parvicorpus (Roewer, 1951) n. comb. (replacement name); Zelotes ruscinensis Simon, 1914 = Zelotes semirufa (L. Koch, 1882) n. syn.; Phlegra simoni L. Koch, 1882 = Phlegra bresnieri Lucas, 1846 n. syn.; Trochosula conspersa (L. Koch, 1882), Lycorma fraisnei (L. Koch, 1882), Lycorma insulana (L. Koch, 1882), Arctosa misella (L. Koch, 1992) and Pirata simplex (L. Koch, 1882) are all retransferred to their original genus Lycosa stat. rev. Cheiracanthium occidentale L. Koch, 1882, Ozyptila furcula L. Koch, 1882 and Zelotes callidus (Simon, 1878) are redescribed

Description of the male of Steatoda ephippiata (Araneae: Theridiidae)

The previously unknown male of Steatoda ephippiata (Thorell, 1875) is described from recently collected material in Tunisia. Some new distribution records for the species are added and all known records are mapped

Bernard LE PERU (2007): Catalogue et répartition des araignées de France

Buchbesprechung: Bernard Le Peru, 2007, Catalogue et répartition des araignées de France, J-C Ledoux, 468 p. Michael J. Roberts, 199

An introductory study of house spiders (Araneae) in Belgium

More than 800 spiders were collected in 43 houses heated in winter, distributed mainly in the northern part of Belgium. Information required for the collections to be eligible for the project was: address, construction year, type of house, and surroundings. The spiders were qualified as ‘house spiders’ or ‘garden spiders’. Of the 93 species collected, 19 could be defined as house spiders. Pholcus phalangioides was the most common, followed by Eratigena atrica and Steatoda triangulosa. Garden spiders enter the house much more often in houses in a rural environment than in those situated in clusters, and mainly in spring. The spiders are most common in autumn when many of them are breeding. The common house spiders colonize houses shortly after their construction

new species and new records of ant eating spiders from mediterranean europe araneae zodariidae

The following new Zodarion species are described from Italy: Zodarion pantaleonii Bosmans & Pantini spec. nov. and Z. pseudonigriceps Bosmans & Pantini spec. nov., both from Sardinia, Z. montesacrense Bosmans spec. nov. and Z. valentii Bosmans, Loverre & Addante spec. nov., both from Puglia, Z. valentii also occurs in Sicily. Zodarion sp., described from Greece in 2009, is the unknown female of Zodarion zorbaBosmans, 2009. Zodarion gracilitibiale Denis, 1934 is new for Italy. New records for 43 other European Zodarion species are presented

Treatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study

Aim Transcatheter aortic valve implantation has become an alternative to surgery in higher risk patients with symptomatic aortic stenosis. The aim of the ADVANCE study was to evaluate outcomes following implantation of a self-expanding transcatheter aortic valve system in a fully monitored, multi-centre ‘real-world' patient population in highly experienced centres. Methods and results Patients with severe aortic stenosis at a higher surgical risk in whom implantation of the CoreValve System was decided by the Heart Team were included. Endpoints were a composite of major adverse cardiovascular and cerebrovascular events (MACCE; all-cause mortality, myocardial infarction, stroke, or reintervention) and mortality at 30 days and 1 year. Endpoint-related events were independently adjudicated based on Valve Academic Research Consortium definitions. A total of 1015 patients [mean logistic EuroSCORE 19.4 ± 12.3% [median (Q1,Q3), 16.0% (10.3, 25.3%)], age 81 ± 6 years] were enrolled. Implantation of the CoreValve System led to a significant improvement in haemodynamics and an increase in the effective aortic valve orifice area. At 30 days, the MACCE rate was 8.0% (95% CI: 6.3-9.7%), all-cause mortality was 4.5% (3.2-5.8%), cardiovascular mortality was 3.4% (2.3-4.6%), and the rate of stroke was 3.0% (2.0-4.1%). The life-threatening or disabling bleeding rate was 4.0% (2.8-6.3%). The 12-month rates of MACCE, all-cause mortality, cardiovascular mortality, and stroke were 21.2% (18.4-24.1%), 17.9% (15.2-20.5%), 11.7% (9.4-14.1%), and 4.5% (2.9-6.1%), respectively. The 12-month rates of all-cause mortality were 11.1, 16.5, and 23.6% among patients with a logistic EuroSCORE ≤10%, EuroSCORE 10-20%, and EuroSCORE >20% (P< 0.05), respectively. Conclusion The ADVANCE study demonstrates the safety and effectiveness of the CoreValve System with low mortality and stroke rates in higher risk real-world patients with severe aortic stenosi

Clinical Outcomes With a Repositionable Self-Expanding Transcatheter Aortic Valve Prosthesis: The International FORWARD Study

Background Clinical outcomes in large patient populations from real-world clinical practice with a next-generation self-expanding transcatheter aortic valve are lacking. Objectives This study sought to document the clinical and device performance outcomes of transcatheter aortic valve replacement (TAVR) with a next-generation, self-expanding transcatheter heart valve (THV) system in patients with severe symptomatic aortic stenosis (AS) in routine clinical practice. Methods The FORWARD (CoreValve Evolut R FORWARD) study is a prospective, single-arm, multinational, multicenter, observational study. An independent clinical events committee adjudicated safety endpoints based on Valve Academic Research Consortium-2 definitions. An independent echocardiographic core laboratory evaluated all echocardiograms. From January 2016 to December 2016, TAVR with the next-generation self-expanding THV was attempted in 1,038 patients with symptomatic, severe AS at 53 centers on 4 continents. Results Mean age was 81.8 ± 6.2 years, 64.9% were women, the mean Society of Thoracic Surgeons Predicted Risk of Mortality was 5.5 ± 4.5%, and 33.9% of patients were deemed frail. The repositioning feature of the THV was applied in 25.8% of patients. A single valve was implanted in the proper anatomic location in 98.9% of patients. The mean aortic valve gradient was 8.5 ± 5.6 mm Hg, and moderate or severe aortic regurgitation was 1.9% at discharge. All-cause mortality was 1.9%, and disabling stroke occurred in 1.8% at 30 days. The expected-to-observed early surgical mortality ratio was 0.35. A pacemaker was implanted in 17.5% of patients. Conclusions TAVR using the next-generation THV is clinically safe and effective for treating older patients with severe AS at increased operative risk. (CoreValve Evolut R FORWARD Study [FORWARD]; NCT02592369